In preclinical models AG014699 (i.v. rucaparib compound) inhibits tumour growth in not only mutant BRCA1/2 models, but also in those with non-BRCA mutant-deficient HR, such as deficient XRCC3 and epigenetically silenced BRCA1 (Drew et al, 2011a). The gene discussed is BRCA1; the disease is neoplasm.